Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

被引：2
|
作者：
Li, Yangzi [1 ]
Liu, Sining [2 ]
Cui, Qingya [3 ]
Liu, Lingling [1 ]
Li, Zheng [3 ]
Cui, Wei [3 ]
Li, Mengyun [3 ]
Zhu, Xiaming [3 ]
Kang, Liqing [4 ]
Yu, Lei [4 ]
Wu, Depei [5 ]
Tang, Xiaowen [3 ]
机构：
[1] Soochow Univ, Affifiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Affifiliated Hosp 1, Suzhou, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[4] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
[5] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Collaborat Innovat Ctr Hematol,Affiliated Hosp 1, Suzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Pitfalls in patenting academic CAR-T cells therapy
    Constantinescu, Catalin
    Constantinescu, Roxana
    Bergthorsson, Jon Thor
    Greiff, Victor
    Tanase, Alina
    Colita, Anca
    Gulei, Diana
    Tomuleasa, Ciprian
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2023, 33 (05) : 339 - 348
  • [42] CAR-T cells, from principle to clinical applications
    Bourbon, Estelle
    Ghesquieres, Herve
    Bachy, Emmanuel
    BULLETIN DU CANCER, 2021, 108 (10) : S4 - S17
  • [43] Optimizing the Manufacture of CAR-T Cells for Clinical Applications
    Mucharla, Roopa
    Anurathapan, Usanarat
    Lapteva, Natalia
    Leen, Ann M.
    Rooney, Cliona
    Vera, Juan F.
    MOLECULAR THERAPY, 2012, 20 : S223 - S223
  • [44] Reducing the risk of biocontamination in gene, cell and CAR-T therapy
    Hansen, Rolf
    Manufacturing Chemist, 2020, 91 (10): : 30 - 31
  • [45] Optimizing the Manufacture of CAR-T Cells for Clinical Applications
    Bajgain, Pradip
    Mucharla, Roopa
    Anurathapan, Usanarat
    Lapteva, Natalia
    Leen, Ann M.
    Heslop, Helen E.
    Rooney, Cliona M.
    Vera, Juan F.
    BLOOD, 2012, 120 (21)
  • [46] FDA advisory committee recommends CAR-T therapy of ALL
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) : 1958 - 1958
  • [47] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
    Wenjie Li
    Lixia Ding
    Wenhua Shi
    Xinyu Wan
    Xiaomin Yang
    Jing Yang
    Tianyi Wang
    Lili Song
    Xiang Wang
    Yani Ma
    Chengjuan Luo
    Jingyan Tang
    Longjun Gu
    Jing Chen
    Jun Lu
    Yanjing Tang
    Benshang Li
    Journal of Translational Medicine, 21
  • [48] NEW ANTIGENS FOR A CAR-T THERAPY IN JUVENILE MYELOMONOCITIC LEUKEMIA
    Matamala, Nerea
    Ruz-Caracuel, Beatriz
    Minguillon, Jordi
    Rodriguez, Carlos
    Escudero, Adela
    Zapata, Alfonso Navarro
    Ferreras, Cristina
    Martinez, Antonio Perez
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S192 - S192
  • [49] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
    Li, Wenjie
    Ding, Lixia
    Shi, Wenhua
    Wan, Xinyu
    Yang, Xiaomin
    Yang, Jing
    Wang, Tianyi
    Song, Lili
    Wang, Xiang
    Ma, Yani
    Luo, Chengjuan
    Tang, Jingyan
    Gu, Longjun
    Chen, Jing
    Lu, Jun
    Tang, Yanjing
    Li, Benshang
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [50] Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia
    Zhang, Xian
    Zhang, Gailing
    Li, Wenqian
    Qiu, Liyuan
    Wang, Dongchu
    Yang, Junfang
    Li, Jingjing
    Lu, Peihua
    BLOOD, 2021, 138
12345